New Innovative Research in Cancer Nanotechnology (IRCN) Funding Opportunity Announcement (R01)

NCI’s Office of Cancer Nanotechnology Research has published a new funding opportunity announcement (FOA) for the Innovative Research in Cancer Nanotechnology (IRCN) initiative, PAR-17-240. All IRCN awards made through this announcement are R01 grants and will be part of the Alliance for Nanotechnology in Cancer network. Due dates are twice per year, with the announcement remaining open until May 2020. The first due date is November 21, 2017.

The purpose of this FOA is to advance the development of innovative research projects addressing major barriers in cancer biology and/or oncology using nanotechnology, with emphasis on the fundamental understanding of nanomaterial interactions with biological systems, mechanisms of nanoparticle delivery in vivo, and characterization of diagnostic devices in vitro.

Investigators with expertise in cancer nanotechnology and/or combined expertise in cancer biology, oncology, chemistry, physics, and materials science are encouraged to apply for this new FOA. Please also note that non-U.S. entities and non-U.S. components of U.S. organizations are eligible to apply for these awards.

Inquiries regarding the IRCN FOA should be directed to Dr. Piotr Grodzinski ( or Dr. Stephanie Morris (